Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. MediWound Ltd.
  6. News
  7. Summary
    MDWD   IL0011316309

MEDIWOUND LTD.

(MDWD)
  Report
Delayed Quote. Delayed Nasdaq - 01/25 04:00:00 pm
2.46 USD   -1.99%
01/24Health Care Stocks Declining This Afternoon
MT
01/24Health Care Stocks Dragged Lower in Broad-Based Equities Selloff
MT
01/24Wall Street Set for Losses Amid Ukraine Crisis
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

MediWound : to Present at Upcoming Investor Conferences

09/06/2021 | 10:11am EST

YAVNE, Israel - MediWound Ltd. (Nasdaq: MDWD) (the 'Company'), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, announced that management will present at the following investor conferences during the month of September 2021.

2021 Wells Fargo Virtual Healthcare Conference

Date: Thursday, September 9, 2021

Presentation Time: 8:00 a.m. Eastern Time

H.C. Wainwright 23rd Annual Global Investment Conference

On-demand corporate presentation is available beginning at 7:00 AM ET on Monday, September 13, 2021

A live webcast of each event will be available on the Events page of the Investors section of the Company's website: www.mediwound.com. A replay of each webcast will be available on the Company's website for approximately 30 days.

About MediWound Ltd.

MediWound is a biopharmaceutical company that develops, manufactures, and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Our strategy leverages our enzymatic technology platform, focused on next-generation bioactive therapies for burn care, wound care and tissue repair.

NexoBrid, our commercial orphan biological product for non-surgical eschar removal of deep-partial and full-thickness thermal burns, is a bromelain-based biological product containing a sterile mixture of proteolytic enzymes that selectively removes burn eschar within four hours without harming surrounding viable tissue. NexoBrid is currently marketed in the European Union and other international markets and is at registration-stage in the U.S. NexoBrid is supported by the U.S. Biomedical Advanced Research and Development Authority (BARDA).

EscharEx, our next-generation bioactive topical therapeutic under development in the U.S. for debridement of chronic and hard to heal wounds. In two Phase 2 studies, EscharEx was well-tolerated and has demonstrated safety and efficacy in the debridement of various chronic and other hard-to-heal wounds, within a few daily applications.

MW005, our topical biological drug for the treatment of non-melanoma skin cancers, is a clinical-stage product candidate under development.

Committed to innovation, we are dedicated to improving quality of care and patient lives. For more information, please visit www.mediwound.com.

Contact:

Jeremy Feffer

Managing Director

LifeSci Advisors

E: jeremy@lifesciadvisors.com

Boaz Gur-Lavie

Chief Financial Officer

MediWound Ltd.

T: 212-915-2568

E: ir@mediwound.com

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about MEDIWOUND LTD.
01/24Health Care Stocks Declining This Afternoon
MT
01/24Health Care Stocks Dragged Lower in Broad-Based Equities Selloff
MT
01/24Wall Street Set for Losses Amid Ukraine Crisis
MT
01/24Health Care Stocks Retreat Premarket Monday
MT
01/24Top Premarket Gainers
MT
01/24MediWound Discloses 'Positive' Data From Phase 2 Study of Leg Ulcer Treatment
MT
01/24MEDIWOUND : Announces Positive Topline Results From Its U.S. Phase 2 Trial of EscharEx for..
PU
01/24MediWound Announces Positive Topline Results From Its U.S. Phase 2 Trial of EscharEx fo..
GL
01/24Mediwound Announces Positive Topline Results from Its U.S. Phase 2 Trial of Escharex fo..
CI
2021MediWound Says Phase 2 Study of EscharEx Treatment for Chronic Wounds Delivers Positive..
MT
More news
Analyst Recommendations on MEDIWOUND LTD.
More recommendations
Financials (USD)
Sales 2021 23,9 M - -
Net income 2021 -13,4 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,02x
Yield 2021 -
Capitalization 67,0 M 67,0 M -
Capi. / Sales 2021 2,81x
Capi. / Sales 2022 2,64x
Nbr of Employees -
Free-Float 57,2%
Chart MEDIWOUND LTD.
Duration : Period :
MediWound Ltd. Technical Analysis Chart | MDWD | IL0011316309 | MarketScreener
Technical analysis trends MEDIWOUND LTD.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 2,46 $
Average target price 6,92 $
Spread / Average Target 181%
EPS Revisions
Managers and Directors
Sharon Malka Chief Executive Officer
Boaz Gur-Lavie Chief Financial Officer
Stephen T. Wills Executive Chairman
Lior Rosenberg Chief Medical Officer
Ety Klinger Chief Research & Development Officer
Sector and Competitors
1st jan.Capi. (M$)
MEDIWOUND LTD.4.24%67
CSL LIMITED-9.68%89 330
WUXI BIOLOGICS (CAYMAN) INC.-7.56%47 444
SAMSUNG BIOLOGICS CO.,LTD.-13.62%44 768
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.-7.34%33 005